Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2021—DiaSorin Molecular received additional federal funding from the Biomedical Advanced Research and Development Authority for the validation and submission of the Simplexa COVID-19 Direct kit and the Simplexa COVID-19 & Flu A/B Direct kit for FDA 510(k) clearance. The company initially received BARDA funding in March 2020 to test, validate, and submit the Simplexa COVID-19 Direct kit for FDA emergency use authorization.
February 2021—The FDA issued an emergency use authorization to Lucira Health for its COVID-19 All-In-One Test Kit, the first COVID-19 diagnostic test for self-testing at home and that provides rapid results.
February 2021—Bio-Rad Laboratories launched an online library called Bio-Rad Western Blotting Learning Center. The center was created to provide researchers an online platform to learn about western blotting and offers information on the science of western blotting, best practices, tips and techniques, as well as guidance on how to troubleshoot experiments. It is available via the company’s website at bio-rad.com/LearnWestern.
February 2021—Beckman Coulter launched the Access SARS-CoV-2 Antigen assay, a high-throughput COVID-19 test available in the U.S., priced at $4 to health care providers, including public and private institutions, governments, and nonprofits.
February 2021—Sysmex America has added the FDA 510(k)-cleared CellaVision DC-1 to its portfolio of CellaVision products for low-volume hematology labs.
February 2021—Qiagen announced that it now retains the exclusive rights to license and distribute the COSMIC database from the Wellcome Sanger Institute for commercial use, effective Jan. 1. COSMIC, the Catalogue of Somatic Mutations in Cancer, is a large, comprehensive resource for exploring the impact of somatic mutations in human cancer. The database is updated continuously and contains more than 37 million coding mutations. More than 20,000 researchers, bioinformaticians, and clinicians worldwide use COSMIC, which is available for download, annotation, and integration.
February 2021—Randox announced that its improved software for the Vivalytic analysis device enables its CE-marked Vivalytic SARS-CoV-2 rapid coronavirus test to deliver results for positive samples in less than 30 minutes.
February 2021—Verichem Laboratories released a liquid-stable, protein-based BR2 Bilirubin Calibrator designed for the calibration of Advanced Instruments’ Advanced BR2 Bilirubin Stat Analyzer. The product has an open-vial stability claim of five days and an unopened shelf-life claim of 14 months at 2° to 8°C. The bilirubin calibrator is packaged in amber serum vials with rubber-lined closures and contains 5.0 mL of standard material, with two vials per kit.
February 2021—PerkinElmer and Horizon Discovery have reached an agreement in which PerkinElmer will acquire Horizon for about $383 million.
February 2021—Novodiax launched two rapid IhcDirect antibody assays, TTF1 and napsin A, for in vitro diagnostic use.
